The content of the invention
It is an object of the invention to solve above-mentioned technical problem, there is provided and one kind can effectively realize medicine sustained and controlled release, andCaptopril pharmaceutical composition with preferable bioavilability and medicine stability.
The technical scheme is that carry out in the following manner：
The pharmaceutical composition of the present invention includes：Drug core, the first coatings, drug coating layer and optional outer coatingsLayer.Drug core includes medicine and pharmaceutical acceptable carrier, and the first coatings comprise at least PEG, phthalic acid ester and PVA；MedicineCoatings comprise at least medicine, mannitol and microcrystalline cellulose；Exterior coating comprises at least HPMC, PEG and titanium dioxide.
Preferably, counted using the gross weight of composition as 100%, the weight proportion of each part is：Drug core accounts forThe 40%-60% of gross weight, the first coatings account for the 5%-20% of gross weight, and drug coating layer accounts for the 20%-50% of gross weight, outsideCoatings account for the 0%-10% of gross weight.
It is furthermore preferred that the weight proportion of each part of composition is：Drug core accounts for the 45%-65% of gross weight, theOne coatings account for the 8%-15% of gross weight, and drug coating layer accounts for the 25%-45% of gross weight, and exterior coating accounts for gross weight1%-5%.
Most preferably, the weight proportion of each part of composition is：Drug core accounts for the 50% of gross weight, the first coatingLayer accounts for the 13% of gross weight, and drug coating layer accounts for the 35% of gross weight, and exterior coating accounts for the 2% of gross weight.
The further preferred captopril pharmaceutical composition composition of the present invention is with proportioning：
A) drug core：Including captopril or its salt, mannitol, microcrystalline cellulose, magnesium stearate；
B) the first coatings：Including PEG, phthalic acid ester, PVA and talcum powder；
C) drug coating layer：Including captopril or its salt, lactose, microcrystalline cellulose, PEG, HPMC, magnesium stearate and twoTitanium oxide；
D) optionally, exterior coating：Including HPMC, PEG, titanium dioxide and talcum powder.
Preferably, the captopril pharmaceutical composition composition is with proportioning：
A) drug core：Counted using label gross weight as 100%, captopril or its salt accounts for 5%-40%, mannitol accounts for30%-60%, microcrystalline cellulose account for 25%-60%, magnesium stearate accounts for 0.1%-5%；
B) the first coatings：Counted using the first coatings gross weight as 100%, PEG accounts for 10%-40%, phthalic acid esterAccount for that 20%-50%, PVA account for 30%-60%, talcum powder accounts for 0.1%-5%；
C) drug coating layer：Counted using drug coating layer gross weight as 100%, captopril or its salt account for 8%-50%, breastSugar accounts for 10%-40%, microcrystalline cellulose accounts for 10%-40%, PEG and account for 10%-20%, HPMC accounting for 10%-30%, hardFatty acid magnesium accounts for 0.1%-5%, titanium dioxide accounts for 0.1%-2%；
D) optionally, exterior coating：Counted using exterior coating gross weight as 100%, HPMC accounts for 30%-80%, PEG and accounted for15%-70%, titanium dioxide account for 0.1%-2%, and talcum powder accounts for 0.1%-5%.
It is furthermore preferred that the captopril pharmaceutical composition composition is with proportioning：
A) drug core：Counted using label gross weight as 100%, captopril or its salt accounts for 8%-35%, mannitol accounts for35%-50%, microcrystalline cellulose account for 25%-50%, magnesium stearate accounts for 0.1%-2%；
B) the first coatings：Counted using the first coatings gross weight as 100%, PEG accounts for 25%-35%, phthalic acid esterAccount for that 25%-40%, PVA account for 33%-45%, talcum powder accounts for 0.1%-3%；
C) drug coating layer：Counted using drug coating layer gross weight as 100%, captopril or its salt account for 8%-50%, breastSugar accounts for 15%-25%, microcrystalline cellulose accounts for 10%-30%, PEG and account for 10%-15%, HPMC accounting for 12%-30%, hardFatty acid magnesium accounts for 0.1%-2%, titanium dioxide accounts for 0.1%-2%；
D) optionally, exterior coating：Counted using exterior coating gross weight as 100%, HPMC accounts for 30%-80%, PEG and accounted for15%-70%, titanium dioxide account for 0.1%-2%, and talcum powder accounts for 0.1%-2%.
As a kind of preferred scheme, the weight of mannitol and microcrystalline cellulose ratio is 1 in drug core:1-1:3, more preferablyFor 1:1、1:2 or 3:4, the weight of lactose and microcrystalline cellulose ratio is 1 in drug coating layer:1-1:3, preferably 1:2.
Particularly preferred, the captopril pharmaceutical composition composition is with proportioning：
A) drug core：Counted using label gross weight as 100%, captopril or its salt account for 8.3%, mannitol and accounted for45%th, microcrystalline cellulose accounts for 45%, magnesium stearate and accounts for 1.7%；
B) the first coatings：Counted using the first coatings gross weight as 100%, PEG accounts for 30%, phthalic acid ester and accounted for28%th, PVA accounts for 40%, talcum powder and accounts for 2%；
C) drug coating layer：Counted using drug coating layer gross weight as 100%, captopril or its salt account for 12%, lactose aboutAccount for 20%, microcrystalline cellulose and account for 30%, PEG and account for 15%, HPMC and account for 20%, magnesium stearate accounting for 1%, titanium dioxide aboutAccount for 2%；
D) optionally, exterior coating：Counted using exterior coating gross weight as 100%, HPMC accounts for 65%, PEG and accounts for 33%, twoTitanium oxide accounts for 1.5%, and talcum powder accounts for 1.5%.
Or：
A) drug core：Counted using label gross weight as 100%, captopril or its salt account for 16.6%, mannitol and accounted for41.2%th, microcrystalline cellulose accounts for 41.2%, magnesium stearate and accounts for 1%；
B) the first coatings：Counted using the first coatings gross weight as 100%, PEG accounts for 30%, phthalic acid ester and accounted for28%th, PVA accounts for 40%, talcum powder and accounts for 2%；
C) drug coating layer：Counted using drug coating layer gross weight as 100%, captopril or its salt account for 24%, lactose aboutAccount for 20%, microcrystalline cellulose and account for 20%, PEG and account for 13%, HPMC and account for 20%, magnesium stearate accounting for 1%, titanium dioxide aboutAccount for 2%；
D) optionally, exterior coating：Counted using exterior coating gross weight as 100%, HPMC accounts for 65%, PEG and accounts for 33%, twoTitanium oxide accounts for 1.5%, and talcum powder accounts for 1.5%.
Or：
A) drug core：Counted using label gross weight as 100%, captopril or its salt account for 16.6%, mannitol and accounted for27.4%th, microcrystalline cellulose accounts for 55%, magnesium stearate and accounts for 1%；
B) the first coatings：Counted using the first coatings gross weight as 100%, PEG accounts for 30%, phthalic acid ester and accounted for28%th, PVA accounts for 40%, talcum powder and accounts for 2%；
C) drug coating layer：Counted using drug coating layer gross weight as 100%, captopril or its salt account for 24%, lactose aboutAccount for 13.3%, microcrystalline cellulose and account for 26.7%, PEG and account for 13%, HPMC and account for 20%, magnesium stearate accounting for 1%, titanium dioxideTitanium accounts for 2%；
D) optionally, exterior coating：Counted using exterior coating gross weight as 100%, HPMC accounts for 65%, PEG and accounts for 33%, twoTitanium oxide accounts for 1.5%, and talcum powder accounts for 1.5%.
Or：
A) drug core：Counted using label gross weight as 100%, captopril or its salt account for 33%, mannitol account for 33%,Microcrystalline cellulose accounts for 33%, magnesium stearate and accounts for 1%；
B) the first coatings：Counted using the first coatings gross weight as 100%, PEG accounts for 30%, phthalic acid ester and accounted for28%th, PVA accounts for 40%, talcum powder and accounts for 2%；
C) drug coating layer：Counted using drug coating layer gross weight as 100%, captopril or its salt account for 47.6%, lactoseAccount for 12%, microcrystalline cellulose and account for 12%, PEG accounting for 10%, HPMC and account for 16%, magnesium stearate accounting for 1%, titanium dioxideAccount for 1.4%；
D) optionally, exterior coating：Counted using exterior coating gross weight as 100%, HPMC accounts for 65%, PEG and accounts for 33%, twoTitanium oxide accounts for 1.5%, and talcum powder accounts for 1.5%.
As a kind of preferred scheme, the total tablet weight of pharmaceutical composition of the present invention is 300mg, respective independent, drug coreIt is 12.5mg, 25mg or 50mg with the content of captopril or its salt in drug coating layer.
The present invention also aims to provide a kind of preparation method of described pharmaceutical composition, methods described includes：With straightPlaten press prepares label, and the first coatings are sprayed on the label, prepares the suspension of drug coating layer, and is coated onAbove-mentioned first coatings outer layer, further, outer layer coating layer is coated on drug coating layer outer layer with the coating method of routine.
The pharmaceutical composition of the present invention has the following advantages that：
1st, discharged and designed by multilayer medicine, realize the long-acting slow-release effect of medicine, in outer layer insoluble drug release and rapidAfter playing drug effect, after time-delay, then the medicine in label is discharged, used twice so as to realize to reach after single medicationThe antihypertensive effect of medicine, patient medication number is reduced, while after night takes, the morning peak phenomenon of hypertension can be avoided.
2nd, by specific prescription screening, the bioavilability of medicine is improved, it is necessary to overcome the general tablet of in the marketThe limitation taken before the meal, reduce influence of the food to insoluble drug release.
3rd, medicine has good result of extraction and preparation stability, meets the security requirement of patient medication.
Figure of description
Fig. 1 writes music line to take drug absorption in the beasle dog body of the pharmaceutical composition of the embodiment of the present invention 3 before the meal；
Fig. 2 takes drug absorption in the beasle dog body of the pharmaceutical composition of the embodiment of the present invention 3 and write music line after the meal.
Embodiment 4 (piece weight 300mg, 12.5mg specifications)
The production technology of reference implementation example 1, prepare agents preparation
The drug absorption degree of experimental example 1 is tested
The 25mg specifications preparation (empty stomach) of the embodiment of the present invention 3 is given to 6 beasle dogs, every dog is administered 1, respectively at0.5 after administration, 1.0,2.0,3.0,4.0,5.0,6.0,7.0,8.0,9.0,10.0,11.0,12.0,13.0,14.0,15.0,Time point of 16.0 hours extracts blood sample, determines the blood concentration (n=6) of different time points, abscissa t=h, and ordinate is averageBlood concentration is μ g/L.
It will be seen from figure 1 that after invention formulation administration 12 as a child interior have absorb twice, and then realize nightAvoid the morning peak of morning drug failure dangerous after administration, while can realize that administration is kept to be administered twice daily 3 times a day, is liftedThe convenience of medication.
The dining of experimental example 2 influences experiment
The 25mg specification preparations of the embodiment of the present invention 3 are given with 6 beasle dogs of experimental example 1, difference is feedingIt is administered in half an hour after, every dog is administered 1, according to the identical point in time sampling of experimental example 1, determines blood concentration, as a result such asShown in Fig. 2.
In terms of comparing result, if dining does not influence on the absorption for taking pharmaceutical preparation of the present invention.
The preparation stability of experimental example 3 is tested
(1) accelerated test
By invention formulation with being placed on 40 ± 2 DEG C after In Aluminium Foil Packing, 6 in the climatic chamber of relative humidity 75 ± 5%Individual month, total miscellaneous and maximum miscellaneous content of list is determined, as a result as shown in table 1.
Table 1：Accelerated test result
(2) long-term stable experiment
By invention formulation with being placed on 25 ± 2 DEG C after In Aluminium Foil Packing, under conditions of relative humidity 60 ± 10%, respectively at0th, sampling detection in 3,6,9,12,18 months, investigates sample long-time stability, as a result as shown in table 2.
Table 2：Long-term stable experiment result
Result is investigated by the preparation stability of Tables 1 and 2 and can be seen that the captopril preparation of the present invention with goodStability, meet drug standard, the drug safety of patient can be ensured.